June 7, 2013
Second Genome Closes Series A With $11.5M
Second Genome Inc., a startup that aims to separate the "good bugs" from the bad inside the human body, has pulled down a third tranche of Series A funding and closed its first institutional round.
The $6.5 million infusion was provided by Advanced Technology Ventures, Morgenthaler and individual backers, and brings the San Francisco-based company's Series A to $11.5 million, Chief Executive Peter DiLaura said.
Valuation was not disclosed. Founded in 2010, Second Genome previously raised seed financing from WavePoint Ventures, Seraph Group and individuals, according to VentureWire records.
The company is one of several research-stage therapeutics companies examining the "biome," a fairly recently coined term that refers to a person's entire microbial make-up.
Information about the biome has been pouring in since scientists sequenced the human genome over a decade ago, Mr. DiLaura said.
Now considered a related science to genomics, biome study is expected to lead to new medical insights, especially related to the human immune system and gastrointestinal system.
Second Genome plans to come out with therapeutics to treat inflammation and metabolic disease, the CEO said.
Full article via subscription only.
By Timothy Hay | San Francisco